adMare
News
April 23 2026
Epitopea Announces Approval of OVACT Clinical Trial Application for CryptiVax-1001 in Advanced High-Grade Serous Ovarian Cancer
April 22 2026
Thryv Therapeutics Commences Patient Dosing in Wave II Clinical Study for Long QT Syndrome and Receives FDA Fast Track Designation for THRV-1268
April 16 2026
adMare BioInnovations Officially Opens M4 Innovation Centre in Vancouver to Support the Growth of Life Sciences Companies in Canada
April 09 2026
Kainova Therapeutics Expands Phase I / II Trial of DT-7012, a Treg-depleting Anti-CCR8 Antibody, with First Patient Dosed in Europe
March 19 2026
Grant to Develop a Machine Learning Platform to Accelerate the Development of the Company's Dualase®-based Therapeutics
March 10 2026
Kainova Therapeutics Announces Positive Phase I Results for DT-9081, an Oral EP4 Receptor Antagonist, in Advanced Solid Tumors
March 03 2026
New Canadian Biotech 26therapeutics Inc. Targets Root Cause of Dry Eye Disease with First-in-Class Therapy
February 10 2026
Kainova Therapeutics Secures $32M CAD to Accelerate Development of Immuno-Oncology and Inflammation Therapies
January 27 2026
Ocythera Secures Seed Financing from adMare BioInnovations and Fonds Impulsion to Advance Therapies for Rare Bone Diseases
January 15 2026
adMare BioInnovations Launches Ocythera: A New Canadian Life Sciences Company Advancing Therapies for Rare Bone Diseases
January 13 2026
Thryv Therapeutics Launches Pivotal Wave II Phase 2/3 Study in Long QT Syndrome Type 2
Newsletter
Stay up to date on the
latest adMare news
Vancouver Innovation Centre
2405 Wesbrook Mall
Vancouver, British Columbia, Canada
V6T 1Z3
T. 604.364.1220
Toronto Office
MaRS Centre Heritage Building
101 College Street, Suite 250
Toronto, Ontario, Canada
M5G 1L7
T. 416.673.8100
Montreal Innovation Centre
7171 Frederick-Banting
Montréal, Québec, Canada
H4S 1Z9
